GleamWall
中文EN

CHRS Coherus Oncology, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1512762 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY44.4%
TTM net income YoY-187.7%
TTM EPS YoY-175.2%
Revenue 3-yr CAGR-36.7%
Net income 3-yr CAGR—

Margins

Gross margin69.8%
Operating margin-275.9%
Net margin-253.4%
FCF margin—
EBITDA margin-274.3%

Returns

ROE-240.5%
ROA-39.5%
ROIC (approx.)—
Asset turnover0.16x

Leverage & solvency

Liabilities / assets85.2%
Debt / equity0.00x
Current ratio1.51x
Interest coverage-15.52x

Cash quality & payout

Operating cash flow / net income1.28x
Accruals ratio11.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$42.17M$26.39M
Cost of revenue$13.81M$8.73M
Gross profit$28.36M$17.66M
R&D expense$108.89M$91.83M
SG&A expense$100.60M$125.48M
Operating income-$181.13M-$199.65M
Interest expense$9.00M$10.73M
Pretax income-$183.12M-$215.39M
Income tax$0$0
Net income$168.02M$28.51M
EBITDA-$179.83M-$198.05M
EPS (basic)1.430.25
EPS (diluted)1.430.25
Weighted avg. shares (diluted)117.14M114.55M
Balance sheet
Cash & equivalents$88.88M$126.25M
Short-term investments$83.25M—
Receivables$17.82M$111.32M
Inventory$3.17M$4.21M
Current assets$206.71M$341.58M
PP&E, net$1.34M$2.58M
Intangibles$20.00M$24.79M
Total assets$258.34M$448.53M
Current liabilities$140.39M$282.98M
Total liabilities$197.33M$580.52M
Shareholders' equity$61.01M-$131.99M
Shares outstanding121.15M115.61M
Cash flow statement
Operating cash flow-$138.51M-$20.44M
Investing cash flow$375.09M$230.32M
Financing cash flow-$273.70M-$186.97M
Depreciation & amortization$1.30M$1.60M
Stock-based compensation$16.97M$27.80M

Free plan shows the latest 2 periods; Pro shows all 14 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.